FDA nominee Heidi Overton plans to speed up medical research
Heidi Overton, Trump's pick to lead the FDA in Washington, stated she will prioritize efficiency to compete with China's biotechnology industry.
Commitment to faster clinical trials
Overton says her direction from President Trump is to go fast. She argues that slow requirements cause investment to flow to China instead. Overton plans to continue Operation Trailblazer to optimize drug development.
Collaboration with career professionals
The nominee intends to work with dedicated career staff at the agency. She wants every person at the FDA to share these goals. The aim is to get cures to patients faster.
Reported by one outlet
Only one outlet has published this. Nothing here has been checked against a second report, so read it as that outlet's account and follow the link below for the original.
Reported by
1 independent outlet. Headline as published. Links open the original report.